Luminex Corporation to Present at JP Morgan Healthcare Conference
January 06 2010 - 11:30AM
PR Newswire (US)
AUSTIN, Texas, Jan. 6 /PRNewswire-FirstCall/ -- Luminex Corporation
(NASDAQ:LMNX) today announced that management will present at the
28th Annual JP Morgan Healthcare Conference to be held January
11-15, 2010, in San Francisco, CA. The investor presentation by
Patrick J. Balthrop, president and chief executive officer, will
begin at 8:30 a.m. Pacific time (11:30 a.m. Eastern time) on
Wednesday, January 13, 2010. The presentation will be webcast live
and may be accessed at Luminex Corporation's website at
http://www.luminexcorp.com/. Simply log on to the web at the
address above, go to the Company section and access the Investor
Relations link. Please go to the website at least 15 minutes prior
to the event to register, download and install any necessary
audio/video software. If you are unable to participate during the
live webcast, the presentation will be archived for six months on
the website using the 'replay' link. ABOUT LUMINEX CORPORATION
Luminex Corporation develops, manufactures and markets proprietary
biological testing technologies with applications throughout the
diagnostic and life sciences industries. The Company's xMAP®
multiplex solutions include an open-architecture, multi-analyte
technology platform that delivers fast, accurate and cost-effective
bioassay results to markets as diverse as pharmaceutical drug
discovery, clinical diagnostics and biomedical research, including
the genomics and proteomics markets. The Company's xMAP Technology
is sold worldwide and is already in use in leading clinical
laboratories as well as major pharmaceutical, diagnostic and
biotechnology companies. Further information on Luminex Corporation
or xMAP technology can be obtained at http://www.luminexcorp.com/.
Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements. The
words "believe," "expect," "intend," "estimate," "anticipate,"
"will," "could," "should" and similar expressions are intended to
further identify such forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995. It is
important to note that the Company's actual results or performance
could differ materially from those anticipated or projected in such
forward-looking statements. Factors that could cause Luminex's
actual results or performance to differ materially include risks
and uncertainties relating to, among others, market demand and
acceptance of Luminex's products, the Company's dependence on
strategic partners for development, commercialization and
distribution of products, concentration of the Company's revenue in
a limited number of strategic partners, fluctuations in quarterly
results due to a lengthy and unpredictable sales cycle and bulk
purchases of consumables, Luminex's ability to scale manufacturing
operations and manage operating expenses, gross margins and
inventory levels, potential shortages of components, competition,
the timing of regulatory approvals, the implementation, including
any modification, of the Company's strategic operating plans, risks
and uncertainties associated with implementing our acquisition
strategy and the ability to integrate acquired companies or
selected assets into our consolidated business operations, as well
as the risks discussed under the heading "Risk Factors" in
Luminex's Reports on Forms 10-K and 10-Q, as filed with the
Securities and Exchange Commission. The forward-looking statements
contained herein represent the judgment of Luminex as of the date
of this press release, and Luminex expressly disclaims any intent,
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change
in Luminex's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based. Contacts: Harriss T. Currie Mimi Torrington Vice
President, Finance and Chief Director of Investor Financial Officer
Relations 512-219-8020 512-219-8020 DATASOURCE: Luminex Corporation
CONTACT: Harriss T. Currie, Vice President, Finance and Chief
Financial Officer, , or Mimi Torrington, Director of Investor
Relations, , both of Luminex Corporation, +1-512-219-8020 Web Site:
http://www.luminexcorp.com/
Copyright
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024